TG Therapeutics Inc (TGTX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 40.57% | 38.10% | -2,421.33% | -1,818.10% | -70,853.95% |
| Operating profit margin | 12.93% | 9.33% | -6,924.20% | -5,154.28% | -179,996.05% |
| Pretax margin | 7.89% | 5.91% | -7,121.54% | -5,204.08% | -183,803.29% |
| Net profit margin | 7.21% | 5.73% | -7,121.54% | -5,204.08% | -183,803.29% |
TG Therapeutics Inc has shown a significant improvement in its profitability ratios over the past few years. The gross profit margin, which indicates the profitability of core operations, started at negative values in 2020 and 2021 but improved to 40.57% by the end of 2024. This demonstrates a remarkable turnaround in the company's ability to generate revenue after covering the cost of goods sold.
Similarly, the operating profit margin, which reflects the company's ability to control operating expenses, improved from negative percentages in 2020 and 2021 to 12.93% in 2024. This indicates that TG Therapeutics has effectively managed its operating costs and has become more efficient in generating profits from its core business activities.
The pretax margin, a measure of overall profitability before taxes, also showed significant improvement over the years. Starting at negative values in 2020 and 2021, the company managed to achieve a pretax margin of 7.89% by the end of 2024. This indicates that TG Therapeutics has been able to enhance its financial performance and generate profits more effectively.
Lastly, the net profit margin, which represents the company's bottom line profitability after all expenses are deducted, improved from negative values in 2020 and 2021 to 7.21% in 2024. This signifies that the company has been successful in controlling costs and increasing its profitability over the years.
Overall, the consistent improvement in profitability ratios reflects the positive trend in TG Therapeutics Inc's financial performance, indicating better management of costs and increased efficiency in generating profits.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.26% | 6.26% | -99.62% | -90.82% | -43.73% |
| Return on assets (ROA) | 4.05% | 3.84% | -102.46% | -91.70% | -44.66% |
| Return on total capital | 8.98% | 9.85% | -148.66% | -113.43% | -51.91% |
| Return on equity (ROE) | 10.52% | 7.90% | -338.53% | -146.78% | -53.79% |
TG Therapeutics Inc has shown a fluctuating trend in its profitability ratios over the years. The Operating return on assets (Operating ROA) deteriorated significantly from 2020 to 2022, indicating inefficiencies in utilizing its assets to generate operating profits. However, there was a noticeable improvement in 2023 and 2024, with positive percentages suggesting better operational performance.
Similarly, the Return on assets (ROA) and Return on total capital ratios followed a similar pattern of decline from 2020 to 2022, reflecting overall lower profitability relative to the assets and capital employed by the company. The positive ROA and Return on total capital values in 2023 and 2024 indicate an improvement in the company's ability to generate profits from its assets and total capital.
The Return on equity (ROE) ratio also exhibited a sharp decline from 2020 to 2022, suggesting a significant drop in profitability available to equity shareholders. However, there was a positive turnaround in 2023 and 2024, indicating better returns to equity holders.
Overall, the company's profitability ratios reflect a challenging period in 2020-2022 but show signs of recovery and improvement in 2023 and 2024. Further analysis of the company's operations and financial performance is recommended to understand the underlying reasons behind these fluctuations.